Bluebird Bio reports FDA lifts clinical hold on lovotibeglogene autotemcel study

Bluebird Bio announced that the FDA lifted its partial clinical hold for patients under the age of 18 in studies evaluating lovotibeglogene autotemcel for sickle cell disease.